It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AZN’s FA Score shows that 2 FA rating(s) are green whileLLY’s FA Score has 4 green FA rating(s), and MRK’s FA Score reflects 3 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AZN’s TA Score shows that 5 TA indicator(s) are bullish while LLY’s TA Score has 6 bullish TA indicator(s), and MRK’s TA Score reflects 5 bullish TA indicator(s).
AZN (@Pharmaceuticals: Major) experienced а +7.32% price change this week, while LLY (@Pharmaceuticals: Major) price change was +6.08% , and MRK (@Pharmaceuticals: Major) price fluctuated +1.42% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.67%. For the same industry, the average monthly price growth was -3.67%, and the average quarterly price growth was -0.12%.
AZN is expected to report earnings on Jul 25, 2024.
LLY is expected to report earnings on Aug 08, 2024.
MRK is expected to report earnings on Jul 30, 2024.
The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
AZN | LLY | MRK | |
Capitalization | 209B | 740B | 332B |
EBITDA | 13.4B | 8.57B | 6.91B |
Gain YTD | 15.195 | 33.485 | 18.893 |
P/E Ratio | 35.30 | 131.13 | 935.64 |
Revenue | 45.8B | 34.1B | 60.1B |
Total Cash | 5.86B | 2.93B | 7.09B |
Total Debt | 28.6B | 25.2B | 35.1B |
AZN | LLY | MRK | ||
---|---|---|---|---|
OUTLOOK RATING 1..100 | 26 | 77 | 12 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 21 Undervalued | 95 Overvalued | 24 Undervalued | |
PROFIT vs RISK RATING 1..100 | 8 | 1 | 5 | |
SMR RATING 1..100 | 57 | 19 | 89 | |
PRICE GROWTH RATING 1..100 | 43 | 7 | 46 | |
P/E GROWTH RATING 1..100 | 78 | 16 | 3 | |
SEASONALITY SCORE 1..100 | n/a | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AZN's Valuation (21) in the Pharmaceuticals Major industry is in the same range as MRK (24) and is significantly better than the same rating for LLY (95). This means that AZN's stock grew similarly to MRK’s and significantly faster than LLY’s over the last 12 months.
LLY's Profit vs Risk Rating (1) in the Pharmaceuticals Major industry is in the same range as MRK (5) and is in the same range as AZN (8). This means that LLY's stock grew similarly to MRK’s and similarly to AZN’s over the last 12 months.
LLY's SMR Rating (19) in the Pharmaceuticals Major industry is somewhat better than the same rating for AZN (57) and is significantly better than the same rating for MRK (89). This means that LLY's stock grew somewhat faster than AZN’s and significantly faster than MRK’s over the last 12 months.
LLY's Price Growth Rating (7) in the Pharmaceuticals Major industry is somewhat better than the same rating for AZN (43) and is somewhat better than the same rating for MRK (46). This means that LLY's stock grew somewhat faster than AZN’s and somewhat faster than MRK’s over the last 12 months.
MRK's P/E Growth Rating (3) in the Pharmaceuticals Major industry is in the same range as LLY (16) and is significantly better than the same rating for AZN (78). This means that MRK's stock grew similarly to LLY’s and significantly faster than AZN’s over the last 12 months.
AZN | LLY | MRK | |
---|---|---|---|
RSI ODDS (%) | 2 days ago47% | 2 days ago68% | 2 days ago60% |
Stochastic ODDS (%) | 2 days ago46% | 2 days ago76% | 2 days ago58% |
Momentum ODDS (%) | 4 days ago63% | 2 days ago66% | 2 days ago51% |
MACD ODDS (%) | 2 days ago67% | 2 days ago60% | 2 days ago49% |
TrendWeek ODDS (%) | 2 days ago56% | 2 days ago70% | 2 days ago54% |
TrendMonth ODDS (%) | 2 days ago54% | 2 days ago71% | 2 days ago38% |
Advances ODDS (%) | 2 days ago55% | 3 days ago69% | 7 days ago50% |
Declines ODDS (%) | 17 days ago44% | 8 days ago53% | 2 days ago43% |
BollingerBands ODDS (%) | 2 days ago49% | 2 days ago37% | 2 days ago50% |
Aroon ODDS (%) | 2 days ago49% | 2 days ago45% | 7 days ago46% |
A.I.dvisor indicates that over the last year, AZN has been loosely correlated with PFE. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if AZN jumps, then PFE could also see price increases.
A.I.dvisor indicates that over the last year, LLY has been loosely correlated with NVS. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if LLY jumps, then NVS could also see price increases.
A.I.dvisor indicates that over the last year, MRK has been loosely correlated with NVS. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if MRK jumps, then NVS could also see price increases.